Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report
Clinical Scorecard: Effective Management of Hepatic Visceral Crisis in HER2-Positive Metastatic Breast Cancer: A Case Study
At a Glance
Category Detail
Condition Hepatic Visceral Crisis in HER2-Positive Metastatic Breast Cancer Key Mechanisms Rapidly worsening organ function due to uncontrolled metastatic progression. Target Population Patients with HER2-positive metastatic breast cancer experiencing hepatic dysfunction. Care Setting Inpatient treatment setting.
Key Highlights
Case of a 51-year-old woman with severe hepatic dysfunction and HER2-positive metastatic breast cancer. Initial treatment included trastuzumab and pertuzumab with dose-reduced paclitaxel. Patient showed early clinical and biochemical improvement. Liver function normalized and CA15–3 levels decreased significantly. Treatment-related changes were observed without evidence of disease progression. Guideline-Based Recommendations
Diagnosis
Diagnosis of hepatic visceral crisis requires rapid assessment of organ function. Management
Initiate therapies capable of achieving a rapid antitumor effect in cases of visceral crisis. Monitoring & Follow-up
Monitor liver function and tumor markers during treatment. Risks
Patients with severe hepatic dysfunction are often excluded from clinical trials. Patient & Prescribing Data
Patients with HER2-positive metastatic breast cancer and hepatic dysfunction.
Early and sustained HER2-targeted therapy can lead to clinical recovery.
Clinical Best Practices
Consider dual HER2 blockade in patients with hepatic visceral crisis. Use dose-adjusted chemotherapy to minimize hepatic strain. Related Resources & Content
